350263-41-1

350263-41-1 structure

Name	ATL 1102

Description	ATL 1102 is a novel second-generation antisense oligonucleotide to CD49d mRNA
Related Catalog	Research Areas >> Others Signaling Pathways >> Cytoskeleton >> Integrin
References	[1]. Duchartre Y, Bachl S, Kim HN, et al. Effects of CD49d-targeted antisense-oligonucleotide on α4 integrin expression and function of acute lymphoblastic leukemia cells: Results of in vitro and in vivo studies. PLoS One. 2017;12(11):e0187684. [2]. Limmroth V, Barkhof F, Desem N, Diamond MP, Tachas G; ATL1102 Study Group. CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS [published correction appears in Neurology. 2015 Jan 6;84(1):105]. Neurology. 2014;83(20):1780-1788.